[The efficacy of topiramate (topamax) in the treatment of resistant epilepsy in children].

Abstract

Authors presented the data on the efficacy and tolerability of the new anticonvulsant drug topiramate (topamax) in the treatment of 110 children aged from 6 months to 16 years with pharmacoresistant types of epilepsy including 42 patients with tuberous sclerosis. The medication dosage varied from 1 to 20 mg/kg daily. As a monotherapy the drug was used in 28 children, in the other cases it was combined with different anticonvulsant medications. Topiramate was effective in 78% patients; complete remission has been achieved in 35% cases. Side-effects were observed in 17% patients but they were transient and did not result in the drug withdrawal. The results of the study allowed to recommend the drug as an add-on and monotherapy in the treatment of resistant epilepsy.

• Authors: M Iu Dorofeeva, A Iu Ermakov, E D Belousova
• Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (Zh Nevrol Psikhiatr Im S S Korsakova) Vol. 105 Issue 11 Pg. 21-3 ( 2005) ISSN: 1997-7298 [Print] Russia (Federation)
• PMID: 16329630 (Publication Type: Journal Article)

Chemical References

• Anticonvulsants
• Triazines
• Topiramate
• Fructose
• Carbamazepine
• Valproic Acid
• Vigabatrin
• Lamotrigine

Topics

• Adolescent
• Anticonvulsants (pharmacokinetics, therapeutic use)
• Carbamazepine (therapeutic use)
• Child
• Child, Preschool
• Drug Resistance
• Drug Therapy, Combination
• Epilepsy (drug therapy)
• Female
• Fructose (analogs & derivatives, therapeutic use)
• Humans
• Infant
• Lamotrigine
• Male
• Topiramate
• Treatment Outcome
• Triazines (therapeutic use)
• Valproic Acid (therapeutic use)
• Vigabatrin (therapeutic use)